Abstract
Type 2 diabetes is associated with increased risk of malignancies, whereas antidiabetic interventions like physical exercise or metformin reduce cancer incidence. A recent publication shows that one diabetes treatment approach, namely incretin-related DPP4 inhibitors, increases metastatic capacity by activating the antioxidant transcription factor NRF2 to decrease reactive oxygen species (ROS) levels.
Original language | English |
---|---|
Pages (from-to) | 959-960 |
Number of pages | 2 |
Journal | Cell Metabolism |
Volume | 23 |
Issue number | 6 |
DOIs | |
State | Published - 14 Jun 2016 |